Considerations on the use of different comparators in pharmacovigilance: A methodological review
British Journal of Clinical Pharmacology · 2023-09 · 89 (9) · 2671-2676
DOI: 10.1111/bcp.15802 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 08.06.2023. Verfasst von Christopher A Gravel und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada. Hauptthemen laut MEDLINE: Pharmacovigilance, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Pharmacovigilance studies based on spontaneous reporting systems use disproportionality analysis methods to identify drug‐event combinations with higher‐than‐expected reporting. Enhanced reporting is deemed as a proxy for a detected signal and is used to generate drug safety hypotheses, which can then be tested in pharmacoepidemiologic studies or randomized controlled trials. Higher‐than‐expected reporting means that the reporting rate of a drug‐event combination of interest is disproportionately higher than the rate in a specific comparator or reference set. Currently, it is unclear which comparator is the most appropriate for use in pharmacovigilance. Moreover, it is also unclear how the selection of a comparator may affect the directionality of the various reporting and other biases. This paper reviews commonly used comparators chosen for signal detection studies (active comparator, class‐exclusion comparator, and full data reference set). We give an overview of the advantages and disadvantages of each method based on examples from the literature. We also touch upon the challenges related to the derivation of general recommendations for the selection of comparators when mining spontaneous reports for pharmacovigilance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada.
- Department of Medicine, McGill University, Montreal, Canada.
- Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada.
- Institute of Clinical Pharmacology and Toxicology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
ORCID-Profile: Antonios Douros
Zitieren
APA
Gravel, C. A., & Douros, A. (2023). Considerations on the use of different comparators in pharmacovigilance: A methodological review. British Journal of Clinical Pharmacology, 89(9), 2671-2676. https://doi.org/10.1111/bcp.15802
Vancouver
Gravel CA, Douros A. Considerations on the use of different comparators in pharmacovigilance: A methodological review. British Journal of Clinical Pharmacology. 2023;89(9):2671-2676. doi:10.1111/bcp.15802
BibTeX
@article{Gravel2023,
author = {Gravel, Christopher A and Douros, Antonios},
title = {Considerations on the use of different comparators in pharmacovigilance: A methodological review},
journal = {British Journal of Clinical Pharmacology},
year = {2023},
volume = {89},
number = {9},
pages = {2671--2676},
doi = {10.1111/bcp.15802}
}
EUVIMED